Data completeness
1/8 — Limited
Drug data last refreshed 11h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
POTIGA is an oral small-molecule tablet approved by the FDA in June 2011 under GSK sponsorship. The specific indication and mechanism of action are not disclosed in available data, limiting assessment of therapeutic area and patient population. As an NDA-approved product in peak lifecycle stage, it represents an established commercial asset.
Peak
Peak lifecycle positioning suggests mature commercial infrastructure with stable field and marketing teams, though competitive pressure at 30% indicates ongoing market defense strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
POTIGA shows zero linked job postings despite peak lifecycle status, suggesting either stable workforce with low turnover or limited hiring expansion. Working on this product likely involves defending market share and optimizing existing infrastructure rather than rapid growth opportunities.
Brand ManagerField Sales Representative
Worked on POTIGA at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.